CoChat

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Human tumours typically harbour a remarkable number of somatic mutations. If presented on major histocompatibility complex class I molecules (MHCI), peptides containing these mutations could potentially be immunogenic as they should be recognized as 'non-self' neo-antigens by the adaptive immune system. Recent work has confirmed that mutant peptides can serve as T-cell epitopes. However, few mutant epitopes have been described because their discovery required the laborious screening of patient tumour-infiltrating lymphocytes for their ability to recognize antigen libraries constructed following tumour exome sequencing. We sought to simplify the discovery of immunogenic mutant peptides by characterizing their general properties. We developed an approach that combines whole-exome and transcriptome sequencing analysis with mass spectrometry to identify neo-epitopes in two widely used murine tumour models. Of the >1,300 amino acid changes identified, ∼13% were predicted to bind MHCI, a small fraction of which were confirmed by mass spectrometry. The peptides were then structurally modelled bound to MHCI. Mutations that were solvent-exposed and therefore accessible to T-cell antigen receptors were predicted to be immunogenic. Vaccination of mice confirmed the approach, with each predicted immunogenic peptide yielding therapeutically active T-cell responses. The predictions also enabled the generation of peptide-MHCI dextramers that could be used to monitor the kinetics and distribution of the anti-tumour T-cell response before and after vaccination. These findings indicate that a suitable prediction algorithm may provide an approach for the pharmacodynamic monitoring of T-cell responses as well as for the development of personalized vaccines in cancer patients.

Overview

Integrity signals

Registry

Crossref · 10.1038/nature14001

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 1,186

Metadata

Authors
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J. R., & Delamarre, L.
Affiliations
  • Genentech (US)
  • Immatics Biotechnologies (Germany) (DE)
Corresponding author
  • Lill, Jennie R.
  • Delamarre, Lélia
Venue
Nature
Published
2014-11-26
Volume
515
Issue
7528
Pages
572-576
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2006759360
Cited by
1,186
References
38
Citations by year
2026: 62 · 2025: 88 · 2024: 74 · 2023: 72 · 2022: 98 · 2021: 135 · 2020: 126 · 2019: 116 · 2018: 101 · 2017: 114 · 2016: 104 · 2015: 89 · 2014: 5
FWCI
42.61
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
T cell epitopes, MHC class I binding, MHC binding prediction, solvent accessibility, cytotoxic T lymphocyte response, pharmacodynamic monitoring, personalized cancer vaccines
MeSH terms
Animals, Female, Immunity, Cellular, Mice, Inbred C57BL, Models, Molecular, Mutation, Neoplasms, Peptides, Mass Spectrometry, Protein Structure, Tertiary, CD8-Positive T-Lymphocytes, Cancer Vaccines, Gene Expression Profiling, Cell Line, Tumor, Immunoprecipitation, Mice, Immunogenetic Phenomena, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. https://app.cochat.ai/papers/10.1038/nature14001
The paper
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J. R., & Delamarre, L. (2014). Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. https://doi.org/10.1038/nature14001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.